Epizyme, Inc. announced that the Company has entered into a collaboration agreement with Foundation Medicine, Inc. to support patient identification and enrollment for Epizyme's ongoing Phase 2 clinical trial of tazemetostat in patients with non-Hodgkin lymphoma (NHL). Foundation Medicine's SmartTrials™ Precision Enrollment Program and FoundationOne® Heme panel will assist in identifying a population of individuals with NHL who harbor EZH2 mutations and constitute specific cohorts in the Epizyme trial.
Tazemetostat is Epizyme's oral, first-in-class EZH2 inhibitor being investigated in multiple ongoing clinical trials. Early clinical data suggest tazemetostat has encouraging clinical activity and a favorable safety profile in patients with relapsed and refractory NHL.
"This agreement exemplifies our commitment to execute enrollment in our ongoing Phase 2 NHL study, particularly patients with EZH2 mutations," said Robert Bazemore, president and chief executive officer of Epizyme. "We are pleased to partner with Foundation Medicine, an industry leader and innovator in molecular information and comprehensive genomic profiling, to advance our tazemetostat clinical program and accelerate identification of patients who may benefit from this therapy."
FoundationOne Heme is Foundation Medicine's validated, comprehensive genomic profiling assay, specifically designed for hematological malignancies and sarcomas, which identifies the unique genomic alterations in an individual's cancer and matches the findings with relevant targeted therapy and clinical trial treatment options for patients. Through this collaboration, Foundation Medicine's SmartTrials Precision Enrollment program will identify individuals across the U.S. living with NHL who harbor EZH2 mutations as detected by FoundationOne Heme in the course of routine clinical care. The treating physicians of these identified patients will be contacted and informed of Epizyme's ongoing Phase 2 study of tazemetostat, including relevant details about the trial, to assist the physician in evaluating tazemetostat as a potential treatment option.